Yael Porat. CEO (Linkedin)
BioGenCell, an Israeli medtech startup that uses stem cells to develop new treatments, has raised $16 million in a seed round of funding led by Marius Nacht. Marius Nacht is the Co-founder and Anchor Investor of aMoon. In 1993, he co-founded the cybersecurity firm Check Point Software Technologies.
Anyone who has followed the daily news coming out of Israel Startup Nation knows that Israeli firms are at the forefront of new medical technologies and Israeli researchers seem to come up with new medical treatments on almost a daily basis. So BioGenCell is not alone.
Just last week Larry Ellison joined a $21.5 million investment in Imagene AI, an Israeli medtech startup that develops AI-based precision medicine for cancer treatment. And Hello Heart, an Israeli medtech startup offering a digital program that helps users to understand and improve their heart health, raised $70 million in Series D financing.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Just last month Israeli scientists made major breakthroughs in treating two of the world’s worst diseases. In April, researchers from Tel Aviv University developed yet another new treatment for cancer. The researchers proved that a drug delivery system based on lipid nanoparticles can utilize RNA to overcome resistance to both chemotherapy and immunotherapy in cancer treatments.
Also in April, researchers from the Weizmann Institute of Science in Israel made a new breakthrough in the treatment of ALS. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease for the famed baseball player from the New York Yankees who died at a young age from the disease, is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control.
Based in Netanya, Israel, BioGenCell is a clinical stage biotechnology company dedicated to using a patient’s own blood to help alleviate microvascular diseases. BioGenCell is located at and has a strategic partnership with Laniado Hospital in Netanya, Israel. BioGenCell offers a patient- and clinician-centered platform that takes a standard blood draw in an outpatient setting with no need for pre-treatment, anaesthesia, or hospitalization. Its patented, 24-hour process is rapid, biologically efficient, and employs a common/unified algorithm to create personalized medicine. Treatment requires only a single injection session in an outpatient setting and appears to have long-lasting effect.
BioGenCell ’s patented technology platform provides a comprehensive solution for most aspects of cellular therapy. It supports both rapid manufacturing and long-term storage (bio-banking) of therapeutic cellular products, which can be used to treat the patient (autologous) or other patients (allogeneous) in order to regenerate damaged tissues in diabetes, heart failure, stroke, peripheral vascular disease including critical limb ischemia, blindness, cancer and a range of immunological diseases
